BIS Removes TTI Subsidiary from Military End-User List

FORT WORTH, Texas--(BUSINESS WIRE)-- A new rule released by the U.S. Commerce Department’s Bureau of Industry and Security (BIS) added a ‘Military End-User’ List to its regulations on military-use and end-user export controls. TTI Electronics Asia PTE Hong Kong Ltd (TTI HK), a subsidiary of U.S.-based TTI, Inc. (TTI), had been incorrectly identified on the draft rule but was removed prior to publication of the final rule.

The action taken by BIS confirms our position that TTI HK is not a ‘Military End User’ nor does it maintain any ties to the Chinese military. Our customers, suppliers, and all business partners can rest assured that TTI and our affiliates globally are fully compliant with all laws and regulations in the locations where we do business, including all U.S. export control requirements.

We express our gratitude to BIS for correcting this error.

About TTI

TTI, Inc., a Berkshire Hathaway company, is an authorized, specialty distributor of electronic components. Founded in 1971, the emphasis on a broad and deep product portfolio, available-to-sell inventory and sophisticated supply chain programs have established TTI as a distributor of choice to manufacturers in the industrial, defense, aerospace, transportation, medical, and communications sectors worldwide. TTI and its wholly owned subsidiaries, the TTI Family of Companies, Mouser Electronics, Sager Electronics and TTI Semiconductor Group employ over 7,000 people in more than 133 locations throughout North America, South America, Europe, Asia and Africa. Globally, the company maintains over 2 million square feet of dedicated warehouse space housing over 850,000 component part numbers. For more information about TTI, visit www.tti.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005669/en/

Cathy Walensky
Corporate Communications Manager
817-740-9000
[email protected]
http://www.tti.com

Source: TTI, Inc.

You May Also Be Interested In

• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
• Could the Next Crypto to Explode Be Hiding in a Presale While BTC and SOL Stall?
• As the Lights Fade, Vivid Sydney 2026 Leaves the City Glowing